insights_auto
Why is TRVN down ၉၉.၂၄%?
Dive Deeperchevron_right
TRVN:OTCMKTS
Trevena Inc
၀.၀၀၀၅၀ US$
arrow_downward
-၉၉.၂၄%(-၀.၀၆၆) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TRVN...
Open
၀.၀၀ US$
High
၀.၀၀ US$
Low
၀.၀၀ US$
Mkt. cap
၄၀၇.၂၁
Avg. vol.
၂၁၀.၀၀
Volume
၄.၁၃ ထောင်
52-wk high
၁.၅၀ US$
52-wk low
၀.၀၀ US$
Beta
၁.၀၇
Shares outstanding
၈.၆၄ သိန်း
No. of employees
၂၃
Open
၀.၀၀ US$
High
၀.၀၀ US$
Low
၀.၀၀ US$
Mkt. cap
၄၀၇.၂၁
Avg. vol.
၂၁၀.၀၀
Volume
၄.၁၃ ထောင်
52-wk high
၁.၅၀ US$
52-wk low
၀.၀၀ US$
Beta
၁.၀၇
Shares outstanding
၈.၆၄ သိန်း
No. of employees
၂၃
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၉ မိနစ်
Michael Burry Warns Stock Market Could Be Months Away From A 2000-Style Reckoning — ‘The Preconditions Seem Set For Fireworks’
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၀ မိနစ်
What Diamondback Energy Holders Bought Into
AOL.com
·
ပြီးခဲ့သည့် ၅၈ မိနစ်
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
MarketWatch
·
ပြီးခဲ့သည့် ၂ နာရီ
Opinion: There is a silent market rotation inside the S&P 500 that’s warning of more weakness ahead
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees၂၃
Founded၂၀၀၇
Headquartersအတ္တလန္တာမြို့, ဂျော်ဂျီယာပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitetrevena.com